Clinical Trials and Research

AbstractBackgroundLeft atrioventricular coupling index (LACI) has emerged as a powerful marker of cardiac remodeling across a variety of cardiac diseases, however…

The plasma protein transthyretin (TTR) transports retinol-binding protein and thyroxine1.Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cause of…

Tafamidis (Vyndaqel/Vyndamax) stabilizes transthyretin (TTR) tetramer, preventing amyloidogenesis. It is the only approved disease-modifying therapy in ATTR…

Patisiran (Onpattro) and inotersen (Tegsedi) are TTR mRNA silencing therapies in hereditary ATTR amyloidosis (hATTR). Patisiran is lipid nanoparticle RNAi (siRNA),…

Acoramidis provides consistent clinical benefit in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) irrespective of baseline atrial…

AbstractBackgroundAdvances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but…

AbstractIntroduction and objectives: To describe the clinical characteristics of patients with cardiac amyloidosis who have undergone heart transplantation (HT).…

Background: Transthyretin amyloidosis (ATTR) is an underdiagnosed cause of cardiomyopathy that is gaining recognition as new treatments become available. The…

Cardiac amyloidosis is a condition in which abnormal proteins, called amyloid, build up in the heart muscle. Over time, these deposits make the heart walls stiffer…

A computerized test that measures how quickly and accurately people perform finger tapping and hand movement tasks was able to detect subtle motor problems in…